EA038979B1 - Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты - Google Patents

Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты Download PDF

Info

Publication number
EA038979B1
EA038979B1 EA201391423A EA201391423A EA038979B1 EA 038979 B1 EA038979 B1 EA 038979B1 EA 201391423 A EA201391423 A EA 201391423A EA 201391423 A EA201391423 A EA 201391423A EA 038979 B1 EA038979 B1 EA 038979B1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
antibody
antigen
binding fragment
variable region
Prior art date
Application number
EA201391423A
Other languages
English (en)
Russian (ru)
Other versions
EA201391423A1 (ru
Inventor
Жилль Бернар Тремблэ
Анна Н. Морайтис
Трейен Сулеа
Марио Филион
Original Assignee
Адс Терапьютикс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адс Терапьютикс Са filed Critical Адс Терапьютикс Са
Publication of EA201391423A1 publication Critical patent/EA201391423A1/ru
Publication of EA038979B1 publication Critical patent/EA038979B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
EA201391423A 2011-03-31 2012-03-28 Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты EA038979B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470063P 2011-03-31 2011-03-31
US201161533346P 2011-09-12 2011-09-12
PCT/CA2012/000296 WO2012129668A1 (en) 2011-03-31 2012-03-28 Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

Publications (2)

Publication Number Publication Date
EA201391423A1 EA201391423A1 (ru) 2014-06-30
EA038979B1 true EA038979B1 (ru) 2021-11-17

Family

ID=46929256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391423A EA038979B1 (ru) 2011-03-31 2012-03-28 Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты

Country Status (24)

Country Link
US (5) US8937163B2 (cg-RX-API-DMAC7.html)
EP (3) EP3173427B1 (cg-RX-API-DMAC7.html)
JP (3) JP6294221B2 (cg-RX-API-DMAC7.html)
KR (2) KR101993259B1 (cg-RX-API-DMAC7.html)
CN (2) CN106146664B (cg-RX-API-DMAC7.html)
AU (1) AU2012234754B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025198A2 (cg-RX-API-DMAC7.html)
CA (3) CA2829105C (cg-RX-API-DMAC7.html)
CY (1) CY1122156T1 (cg-RX-API-DMAC7.html)
DK (2) DK3173427T3 (cg-RX-API-DMAC7.html)
EA (1) EA038979B1 (cg-RX-API-DMAC7.html)
ES (2) ES2743913T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191590T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045943T2 (cg-RX-API-DMAC7.html)
IL (3) IL228434B (cg-RX-API-DMAC7.html)
LT (1) LT3173427T (cg-RX-API-DMAC7.html)
MX (1) MX352373B (cg-RX-API-DMAC7.html)
PL (1) PL3173427T3 (cg-RX-API-DMAC7.html)
PT (1) PT3173427T (cg-RX-API-DMAC7.html)
RS (1) RS59080B1 (cg-RX-API-DMAC7.html)
SI (1) SI3173427T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900505T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012129668A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307027B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
DK3173427T3 (da) * 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
IN2014CN04690A (cg-RX-API-DMAC7.html) 2012-01-09 2015-09-18 Alethia Biotherapeutics Inc
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
NZ754811A (en) 2017-02-08 2023-06-30 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
IL266153A (en) * 2019-04-18 2019-07-31 Aharon Anat Extracellular vesicles derived from t cells containing a chimeric antigen receptor
GB201908128D0 (en) * 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP4274900A4 (en) * 2021-01-07 2024-10-23 National Research Council of Canada TIGHTLY REGULATED INDUCABLE EXPRESSION SYSTEM FOR THE PRODUCTION OF BIOLOGICAL PRODUCTS USING STABLE CELL LINES
AU2023321962A1 (en) 2022-08-12 2025-02-20 Epibiologics, Inc. Degradation of egfr using a bispecific binding agent
EP4619437A2 (en) 2022-11-18 2025-09-24 Epibiologics, Inc. Degradation of cmet using a bispecific binding agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060186A1 (en) * 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US662392A (en) 1899-12-12 1900-11-27 Friedrich Wilhelm Buehne Method of making metal wool.
DK365785A (da) 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
US5075447A (en) 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
US5585279A (en) 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
GB8601646D0 (en) 1986-01-23 1986-02-26 Davidson R S Binding assay & reagent
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
JPH07110852B2 (ja) 1989-12-28 1995-11-29 ジ・アップジョン・カンパニー 二芳香族置換抗ａｉｄｓ化合物
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
AU4017695A (en) 1994-10-28 1996-05-23 Procept, Inc. Ruthenium complexes and their use as immunosuppressive agents
US5708022A (en) 1994-10-28 1998-01-13 Procept, Inc. Method for inhibiting immune response
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU755913B2 (en) 1997-06-18 2003-01-02 Masad Damha Nucleic acid biosensor diagnostics
AU1824899A (en) 1997-12-15 1999-07-05 Joseph R Lakowicz Method and composition for characterizing a sample containing a sample lipid andan assay kit
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
GB2361237A (en) 1998-05-13 2001-10-17 Diversys Ltd Selection system
WO1999058546A1 (en) 1998-05-13 1999-11-18 Ludwig Institute For Cancer Research Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020106678A1 (en) 1998-06-30 2002-08-08 Robishaw Janet D. cDNA clones encoding human G protein gamma subunits
CA2336475A1 (en) 1998-07-02 2000-01-13 Christopher J. Dinsmore Inhibitors of prenyl-protein transferase
US6288221B1 (en) 1998-08-20 2001-09-11 Duke University Methods of synthesis of halogen base-modified oligonucleotides and subsequent labeling with a metal-catalyzed reaction
AU6136599A (en) 1998-09-08 2000-03-27 University Of Maryland At Baltimore Low frequency modulation sensors using nanosecond fluorophores
US6806089B1 (en) 1998-09-08 2004-10-19 University Of Maryland, Baltimore Low frequency modulation sensors using nanosecond fluorophores
WO2000023448A1 (en) 1998-10-22 2000-04-27 Moheno Phillip B B Novel pterin antineoplastic agents
CA2348703A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000056743A1 (en) 1999-03-19 2000-09-28 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6872519B1 (en) 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001046209A1 (en) 1999-12-20 2001-06-28 Fluorrx, Inc. Fluorescent probes
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US20030215860A1 (en) 2000-02-29 2003-11-20 Millennium Pharmaceuticals, Inc. Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
AU2001269836A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
AU2002214531A1 (en) 2000-07-03 2002-01-30 Curagen Corporation Proteins and nucleic acids encoding same
US20050053930A1 (en) 2000-07-18 2005-03-10 David Anderson Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7030236B2 (en) 2001-03-09 2006-04-18 Mona Savitri Jhaveri Antisense oligonucleotides tarageting folate receptor alpha, and the use thereof
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030065157A1 (en) 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
EP1390511B1 (en) 2001-05-07 2008-03-12 National Research Council Of Canada Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
MXPA03011979A (es) 2001-06-18 2005-04-08 Eos Biotechnology Inc Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
US20040053824A1 (en) 2001-06-29 2004-03-18 Tang Y Tom Extracellular matrix and cell adhesion molecules
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US7528141B2 (en) 2001-08-31 2009-05-05 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
BRPI0212215B8 (pt) 2001-08-31 2021-07-27 Btg Int Ltd compostos de ciclopenta[g]quinazolina anticâncer, uso dos mesmos para o tratamento de câncer e composição farmacêutica compreendendo dito composto
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
GEP20074045B (en) 2001-11-19 2007-02-26 Elan Pharm Inc (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2003047526A2 (en) 2001-11-30 2003-06-12 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
JP2005525096A (ja) 2002-01-09 2005-08-25 ユニバーシティ オブ ローザンヌ Ｊｎｋシグナル伝達経路の細胞浸透性ペプチドインヒビター
DE60315949T2 (de) 2002-01-16 2008-06-12 Biocompatibles Uk Ltd., Farnham Polymerkonjugate
US7501485B2 (en) 2002-01-28 2009-03-10 Keraplast Technologies, Ltd. Bioactive keratin peptides
US6962910B2 (en) 2002-02-01 2005-11-08 Virginia Tech Intellectual Properties, Inc. Supramolecular complexes as photoactivated DNA cleavage agents
AU2003225573A1 (en) 2002-02-13 2003-09-04 The Government Of The United States Of America As Represented By The Secretary, Department Of He Identification of ovarian cancer tumor markers and therapeutic targets
DE10206616A1 (de) 2002-02-15 2003-09-04 Qiagen Gmbh Verfahren zur Reduktion der Background-Kontamination nach Markierungsreaktionen
JP2005533000A (ja) 2002-03-05 2005-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｍｄａ−７に関与する免疫誘導を増強する方法
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
CA2485691A1 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
WO2004030615A2 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1422242A1 (en) 2002-11-22 2004-05-26 Emory University Plastic and elastic protein copolymers
WO2004076622A2 (en) 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
WO2004087874A2 (en) 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides
CA2526069A1 (en) 2003-05-20 2004-12-02 Cellpep Sa Modified antiviral peptides with increased activity and cell membrane affinity
EP1636363A1 (en) 2003-05-21 2006-03-22 GeneSense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2005021710A2 (en) 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
US20060078941A1 (en) 2003-06-09 2006-04-13 Santin Alessandro D Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
US20070027075A1 (en) 2003-06-09 2007-02-01 Smithrud David B Compositions and methods for targeted drug delivery
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0318096D0 (en) 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20070178458A1 (en) 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7202234B2 (en) 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
CA2551064A1 (en) 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusale M Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
US20050202020A1 (en) 2004-01-09 2005-09-15 Jeffrey Ross Diagnosing and treating cancer
WO2005076979A2 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
US7666583B2 (en) 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
US20070203060A1 (en) 2004-03-01 2007-08-30 Zvi Sidelman Casein Derived Peptides And Therapeutic Uses Thereof
JP5017107B2 (ja) 2004-07-06 2012-09-05 ワーウィック イフェクト ポリマーズ リミテッド ポリペプチド等と反応し得る官能基を含むリビングラジカル重合開始剤、それを用いて得られる櫛形ポリマー、それから得られるポリペプチド複合体及び薬剤
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
US20080280317A1 (en) 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
JP2008512490A (ja) 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
WO2006044335A2 (en) 2004-10-14 2006-04-27 The Board Of Trustees Of The University Of Arkansas Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
US7429567B2 (en) 2005-01-04 2008-09-30 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
AU2006209543B2 (en) 2005-01-27 2009-04-30 Asahi Kasei Pharma Corporation Six-membered heterocyclic compound and the use thereof
US8007811B2 (en) 2005-02-14 2011-08-30 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
US20090075832A1 (en) 2005-02-24 2009-03-19 Cemines, Inc Compositions and Methods for Classifying Biological Samples
EP1861498A4 (en) 2005-03-17 2009-06-24 Ca Nat Research Council EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME
CN101189229A (zh) 2005-03-17 2008-05-28 哈佛大学校长及研究员协会 阿韦艾利酰胺、斯特伐希丁b和其类似物的合成
FR2885525B1 (fr) 2005-05-13 2009-09-18 Urodelia Sa Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
PT1904084E (pt) 2005-06-13 2013-07-22 Cleveland Clinic Foundation Métodos de proteção contra apoptose mediante uso de lipopéptidos
AU2006259415B2 (en) 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
AU2006261845C1 (en) 2005-06-27 2013-05-16 Exelixis Patent Company Llc Imidazole based LXR modulators
WO2007005249A2 (en) 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US7494788B2 (en) 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US7820790B2 (en) 2005-07-13 2010-10-26 Amgen Mountain View Inc. IL-6 binding proteins
US20090005268A1 (en) 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers
GB0516058D0 (en) 2005-08-04 2005-09-14 Oxford Genome Sciences Uk Ltd New protein isoforms and uses thereof
GB0517293D0 (en) 2005-08-24 2005-10-05 Cancer Rec Tech Ltd Vectors and uses thereof
CA2621067C (en) 2005-09-15 2014-04-29 Alk-Abello A/S A method for quantification of allergens
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP1954274B8 (en) 2005-11-10 2011-01-12 ChemoCentryx, Inc. Substituted quinolones and methods of use
ATE524068T1 (de) 2005-11-23 2011-09-15 Merck Sharp & Dohme Verfahren zur herstellung eines 2-phenyl-1h- phenantrhoä9,10-düimidazol-derivates
KR101049859B1 (ko) 2007-11-28 2011-07-19 대한민국 Ｎ-말단 ｐＩ 값 조절에 의한 수용성 재조합 단백질 생산방법
EP2004686A1 (en) 2006-03-06 2008-12-24 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
CA2645277A1 (en) 2006-03-09 2007-09-13 Wadih Arap Compositions and methods based on peptide binding profiling
EP1996629A2 (en) 2006-03-10 2008-12-03 Warwick Effect Polymers Ltd. Polymers
WO2007110755A1 (en) 2006-03-27 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of cardiovascular inflammation
CA2649800C (en) 2006-04-20 2016-09-20 Kringle Pharma Inc. Hgf precursor protein variant and active protein thereof
WO2007131191A2 (en) 2006-05-05 2007-11-15 Perkinelmer Life And Analytical Sciences Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
CA2900402C (en) 2006-05-08 2018-01-16 Adaerata, Limited Partnership Pcsk9 polypeptide, ligand to said polypeptide, kits and methods using said ligands
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US20120128661A1 (en) 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
WO2008002267A1 (en) 2006-06-28 2008-01-03 Rgb Technologies Ab A sensor kit and a system for detecting an analyte in a test environment
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008012362A2 (en) 2006-07-27 2008-01-31 Oxford Genome Sciences (Uk) Ltd New protein isoforms and uses thereof
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008029031A2 (fr) 2006-09-07 2008-03-13 Laurence Faure Test pharmaco diagnostique ciblant l' oncologie
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
CN101663308A (zh) 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
WO2008074004A2 (en) * 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
WO2008082887A2 (en) 2006-12-28 2008-07-10 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
CA2675032A1 (en) 2007-01-09 2008-07-17 Cleveland Biolabs, Inc. Methods for increasing and mobilizing hematopoietic stem cells
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
WO2008124483A1 (en) 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
WO2009009186A2 (en) 2007-04-13 2009-01-15 The Regents Of The University Of California Receptors useful for gas phase chemical sensing
US20080306007A1 (en) 2007-04-30 2008-12-11 Newcastle Innovation Limited Agents for prophylaxis or treatment of neurological related diseases and conditions
EP2155177A2 (en) 2007-04-30 2010-02-24 Intezyne Technologies Incorporated Modification of biological targeting groups for the treatment of cancer
US8143372B2 (en) 2007-05-21 2012-03-27 Children's Hospital & Research Center Oakland Synthetic regulators of ferritin protein nanocage pores and methods of use thereof
WO2008151146A2 (en) 2007-06-01 2008-12-11 Digitab, Inc. Peptide arrays and methods of use
WO2009004329A1 (en) 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US9018138B2 (en) 2007-08-16 2015-04-28 The Johns Hopkins University Compositions and methods for generating and screening adenoviral libraries
KR20100087283A (ko) 2007-09-07 2010-08-04 심포젠 에이/에스 항­ｒｓｖ 항체의 재조합 제조 방법
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN108196072A (zh) 2007-11-05 2018-06-22 北欧生物科技公司 用于进行cvd风险评估的生物化学标志物
US20100298368A1 (en) 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
EP2071334A1 (en) 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
US20110165223A1 (en) 2008-01-02 2011-07-07 The Johns Hopkins University Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
EP2269070A1 (en) 2008-03-14 2011-01-05 DNAR, Inc Dna repair proteins associated with triple negative breast cancers and methods of use thereof
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
WO2009134370A2 (en) 2008-04-30 2009-11-05 University Of Vermont And State Agricultural College Methods and products relating to gsk3 beta regulation
CA2723824C (en) 2008-05-09 2022-12-06 Surmodics Pharmaceuticals, Inc. Biocompatible and biodegradable elastomeric polymers
US20110123637A1 (en) 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation
TWI403319B (zh) 2008-07-03 2013-08-01 Panmira Pharmaceuticals Llc 前列腺素ｄ2受體之雜烷基拮抗劑
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
CA2730428A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
PT2328893E (pt) 2008-08-08 2013-06-27 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033220A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
DK2451844T3 (en) * 2009-07-10 2015-07-27 Innate Pharma Tlr3-retention agents
EP2486149B1 (en) 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
WO2011054112A1 (en) * 2009-11-03 2011-05-12 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of kidney associated antigen 1
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
US20110233107A1 (en) 2010-03-23 2011-09-29 Emily Jainine Lockett Personal Cosmetic Palette
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
IN2014CN04690A (cg-RX-API-DMAC7.html) 2012-01-09 2015-09-18 Alethia Biotherapeutics Inc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060186A1 (en) * 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUDNICK, S.I. et al., "Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors", Cancer Research, March 15, 2011, Vol. 71, No. 6, p. 2250-2259, ISSN: 0008-5472, the whole document *

Also Published As

Publication number Publication date
CY1122156T1 (el) 2020-11-25
LT3173427T (lt) 2019-09-10
IL228434B (en) 2018-05-31
US20140140990A1 (en) 2014-05-22
JP6650432B2 (ja) 2020-02-19
SMT201900505T1 (it) 2019-11-13
ES2615387T3 (es) 2017-06-06
EP3511345A1 (en) 2019-07-17
AU2012234754A1 (en) 2013-10-10
CA2829105A1 (en) 2012-10-04
CN103492418B (zh) 2016-06-29
JP6294221B2 (ja) 2018-03-14
US20160304605A1 (en) 2016-10-20
PT3173427T (pt) 2019-09-17
KR102140984B1 (ko) 2020-08-06
EP2691421B1 (en) 2016-11-09
BR112013025198A2 (pt) 2018-12-04
US10597450B2 (en) 2020-03-24
US8937163B2 (en) 2015-01-20
EP3173427A1 (en) 2017-05-31
IL228434A0 (en) 2013-12-31
ZA201307027B (en) 2016-08-31
KR101993259B1 (ko) 2019-06-27
ES2743913T3 (es) 2020-02-21
WO2012129668A1 (en) 2012-10-04
PL3173427T3 (pl) 2019-11-29
SI3173427T1 (sl) 2019-08-30
JP2020074785A (ja) 2020-05-21
HRP20191590T1 (hr) 2019-11-29
DK2691421T3 (en) 2017-02-20
CA2893376A1 (en) 2012-10-04
KR20190074325A (ko) 2019-06-27
NZ615694A (en) 2015-01-30
MX2013011354A (es) 2014-06-11
IL266452B (en) 2020-10-29
CA2888908A1 (en) 2012-10-04
MX352373B (es) 2017-11-22
CA2829105C (en) 2019-09-24
CN106146664B (zh) 2021-09-07
US9393302B2 (en) 2016-07-19
CN103492418A (zh) 2014-01-01
IL266452A (en) 2019-06-30
US9828426B2 (en) 2017-11-28
CN106146664A (zh) 2016-11-23
EP3173427B1 (en) 2019-06-19
EA201391423A1 (ru) 2014-06-30
IL258914A (en) 2018-07-31
DK3173427T3 (da) 2019-08-05
EP2691421A1 (en) 2014-02-05
EP2691421A4 (en) 2014-11-05
US20180291099A1 (en) 2018-10-11
US20210054067A1 (en) 2021-02-25
JP2018075018A (ja) 2018-05-17
AU2012234754B2 (en) 2016-09-29
JP2014515600A (ja) 2014-07-03
RS59080B1 (sr) 2019-09-30
KR20140033014A (ko) 2014-03-17
HUE045943T2 (hu) 2020-02-28
US20150209427A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
US10597450B2 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
US9855291B2 (en) Anti-kidney associated antigen 1 (KAAG1) antibodies
EA034414B1 (ru) Способ лечения тройного негативного рака молочной железы
HK40011472A (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1238268B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1238268A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1193835B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1193835A (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
NZ615694B2 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
HK1234432A (en) Antibodies that specifically block the biological activity of a tumor antigen
HK1234432A1 (en) Antibodies that specifically block the biological activity of a tumor antigen